| Nov 7 |
Arcturus Therapeutics: Q3 Earnings Snapshot
|
| Nov 7 |
Arcturus Therapeutics GAAP EPS of -$0.26 beats by $0.88, revenue of $41.67M beats by $5.08M
|
| Nov 7 |
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
|
| Nov 6 |
Arcturus Therapeutics Q3 2024 Earnings Preview
|
| Nov 4 |
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect
|
| Oct 31 |
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024
|
| Oct 30 |
Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock?
|
| Oct 24 |
Investing in Arcturus Therapeutics Holdings (NASDAQ:ARCT) five years ago would have delivered you a 76% gain
|
| Oct 23 |
A slow start for self-amplifying mRNA vaccines
|
| Oct 1 |
Unveiling 3 Analyst Insights On Arcturus Therapeutics
|
